Wellington Partners

Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors

Retrieved on: 
Monday, December 18, 2023

"We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome.

Key Points: 
  • "We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome.
  • "Peter is a recognized leader in the biotech industry and his extensive experience in corporate strategy and drug development will be invaluable to Enterome’s future growth and success.
  • I’d also like to thank Roger for his invaluable contributions to Enterome during his time on the Board."
  • Dr. Hirth possesses a wealth of experience and an exceptional track record in the biopharmaceutical industry.

EQS-News: Wellington Partners promotes Johannes Fischer and Varun Gupta to Partner

Retrieved on: 
Tuesday, November 7, 2023

Munich, Germany - Wellington Partners, a leading European venture capital firm investing in early- and growth-stage life science companies, today announced the promotion of Dr. Johannes Fischer and Dr. Varun Gupta to Partner, effective immediately.

Key Points: 
  • Munich, Germany - Wellington Partners, a leading European venture capital firm investing in early- and growth-stage life science companies, today announced the promotion of Dr. Johannes Fischer and Dr. Varun Gupta to Partner, effective immediately.
  • Johannes joined Wellington in 2020 supporting the firm’s existing medical device and digital health portfolio.
  • Prior to joining Wellington, Varun interned at Ysios Capital in Barcelona and assisted the investment team at Forbion in Amsterdam/Naarden.
  • Regina Hodits, Managing Partner of Wellington Partners, commented: “We are grateful for Johannes and Varun’s significant contribution during the past years.

EQS-News: Inaugural BIOTECH SUMMIT AUSTRIA Sets the Agenda for Emerging Biotech Innovation

Retrieved on: 
Tuesday, October 17, 2023

The first BIOTECH SUMMIT AUSTRIA - a milestone event for the Austrian and international biotechnology community - concluded on Friday in Graz, after two days of insightful discussions and networking.

Key Points: 
  • The first BIOTECH SUMMIT AUSTRIA - a milestone event for the Austrian and international biotechnology community - concluded on Friday in Graz, after two days of insightful discussions and networking.
  • The event, co-hosted by BIOTECH AUSTRIA, the pioneering association for biotechnology in Austria, and the dynamic styrian cluster organization Human.technology Styria, left a lasting impression on the industry.
  • Peter Llewellyn-Davies, President of BIOTECH AUSTRIA, reflected on the significance of this first summit, stating, "The BIOTECH SUMMIT AUSTRIA is an exceptional platform where major players from the industry come together to delve into the latest innovative trends and developments in biotechnology and associated technologies.
  • BIOTECH SUMMIT AUSTRIA, please visit the BIOTECH SUMMIT AUSTRIA Website .

Brennan Hires Larry DiVito as Senior Vice President, Development

Retrieved on: 
Tuesday, July 25, 2023

ROSEMONT, Ill., July 25, 2023 /PRNewswire/ -- Brennan Investment Group, a private real estate investment firm that acquires, develops, and operates industrial facilities throughout the United States, is pleased to announce the appointment of Larry DiVito as Senior Vice President, Development. Larry brings over 30 years of experience in real estate development and construction to his new role at Brennan Investment Group.

Key Points: 
  • ROSEMONT, Ill., July 25, 2023 /PRNewswire/ -- Brennan Investment Group, a private real estate investment firm that acquires, develops, and operates industrial facilities throughout the United States, is pleased to announce the appointment of Larry DiVito as Senior Vice President, Development.
  • Larry brings over 30 years of experience in real estate development and construction to his new role at Brennan Investment Group.
  • In his new position as Senior Vice President, Development, Larry will play a pivotal role in Brennan's development activities.
  • "We are thrilled to welcome Larry DiVito as our Senior Vice President, Development," said Michael Brennan, Brennan's Chairman and Co-Founder.

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Retrieved on: 
Thursday, March 16, 2023

Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further development of its designer recombinases, a novel gene editing platform to transform the treatment of severe diseases.

Key Points: 
  • Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further development of its designer recombinases, a novel gene editing platform to transform the treatment of severe diseases.
  • We believe our pioneering technology will allow us to shatter the boundaries that exist in gene editing methods today,” said Anne-K. Heninger, PhD, Co-Founder and Chief Executive Officer of Seamless Therapeutics.
  • Seamless Therapeutics has a first-mover position with its innovative platform capable of modifying the long held standard recombination technology into a universal gene editing tool with unprecedented specificity.
  • We are excited to support Seamless Therapeutics in its pursuit of taking a leadership position in the rapidly evolving gene editing arena,” added Karl Nägler, PhD, Managing Partner at Wellington Partners.

Carisma Therapeutics Closes Merger with Sesen Bio

Retrieved on: 
Tuesday, March 7, 2023

PHILADELPHIA, March 7, 2023 /PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, and Sesen Bio, Inc. ("Sesen Bio"), announced today the closing of their previously announced merger. The combined company will operate under the name Carisma Therapeutics Inc. and shares of its common stock will commence trading under the ticker symbol "CARM" on March 8, 2023 on the Nasdaq Capital Market.

Key Points: 
  • Shares of Carisma to commence trading on Nasdaq under new ticker symbol "CARM" on March 8, 2023
    Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical readouts across Carisma programs
    PHILADELPHIA, March 7, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, and Sesen Bio, Inc. ("Sesen Bio"), announced today the closing of their previously announced merger.
  • Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "I want to thank the entire Sesen Bio team for their steadfast commitment to our mission to save and improve lives.
  • Patients, caregivers and investigators around the world have been important advocates of Sesen Bio and I want to thank them for their support.
  • SVB Securities acted as the exclusive financial advisor to Sesen Bio for the transaction, and Hogan Lovells US LLP served as Sesen Bio's legal counsel.

Nosto raises $16M as it launches site search within its Commerce Experience Platform (CXP)

Retrieved on: 
Thursday, February 23, 2023

NEW YORK, Feb. 23, 2023 /PRNewswire-PRWeb/ -- Nosto, the world's leading Commerce Experience Platform (CXP), has today announced the closure of its latest funding round of $16M USD, from Mandatum Asset Management's Growth Equity team (MAM GE).Already backed by OpenOcean, Wellington Partners, Eurazeo, and Tesi among others, the latest round from MAM GE accelerates Nosto's mission to make every impression relevant.

Key Points: 
  • "Merchants using Nosto are growing quickly, and merchants using Nosto on the Shopify platform are growing quicker still.
  • This investment will help us continue scaling our Commerce Experience Platform, supporting brands in their own growth ambitions.
  • "Since launching site search natively within our CXP , we're uniquely positioned to disrupt the product discovery space.
  • "This raise allows us to accelerate our innovation and continue developing our Commerce Experience Platform.

TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation

Retrieved on: 
Tuesday, December 6, 2022

TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation

Key Points: 
  • TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation
    Paris, France and Munich, Germany, December 6, 2022 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the second closing and completion of its Series C financing round, successfully raising a total of €51m for the round.
  • Topaz is an innovative device developed to help patients suffering from severe tricuspid regurgitation without the need for open heart surgery.
  • Tricuspid regurgitation occurs when the tricuspid valve fails to close properly, causing blood to flow backwards into the right atrium.
  • Therefore, physicians are urgently seeking minimally invasive, low-risk solutions to improve clinical outcomes in TR patients.

UroMems Initiates First-in-Human Study of Its Smart Implant to Treat Stress Urinary Incontinence

Retrieved on: 
Tuesday, November 29, 2022

GRENOBLE, France, Nov. 29, 2022 /PRNewswire/ -- UroMems, a global company developing breakthrough, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-in-human implant of the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) investigational device to treat SUI. This initial clinical study is a key milestone in the development of UroActive.

Key Points: 
  • GRENOBLE, France, Nov. 29, 2022 /PRNewswire/ -- UroMems , a global company developing breakthrough, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-in-human implant of the UroActive System, the first smart automated artificial urinary sphincter (AUS) investigational device to treat SUI.
  • This initial clinical study is a key milestone in the development of UroActive.
  • "This is a historic milestone for UroMems, patients, physicians and the industry as this is a first-of-its-kind fully automated AUS implant designed to treat SUI in both men and women," said Hamid Lamraoui, UroMems chief executive officer and co-founder.
  • UroActive is the first smart active implant that treats SUI, powered by a MyoElectroMechanical System (MEMS).

NEUWAY Pharma Appoints Dr Oliver Ernst as Chief Executive Officer and Dr Thomas Christoph as Chief Development Officer

Retrieved on: 
Tuesday, September 20, 2022

NEUWAY Pharma GmbH, NEUWAY , a highly innovative biotechnology company specializing in the delivery of mRNA and other biotherapeutic drug molecules to the CNS and other tissues via its proprietary EnPC drug-delivery technology, today announced two new appointments in its senior leadership team: Dr Oliver Ernst, formerly NEUWAY's Chief Operating Officer, was promoted to Chief Executive Officer, and Dr Thomas Christoph was appointed as new Chief Development Officer.

Key Points: 
  • NEUWAY Pharma GmbH, NEUWAY , a highly innovative biotechnology company specializing in the delivery of mRNA and other biotherapeutic drug molecules to the CNS and other tissues via its proprietary EnPC drug-delivery technology, today announced two new appointments in its senior leadership team: Dr Oliver Ernst, formerly NEUWAY's Chief Operating Officer, was promoted to Chief Executive Officer, and Dr Thomas Christoph was appointed as new Chief Development Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220920005693/en/
    Dr Ernst, who joined NEUWAY in 2019 as Chief Operating Officer and Managing Director, will now lead the company as CEO.
  • NEUWAY co-founder Dr. Heiko Manninga will continue to serve in his existing role as Chief Scientific Officer and Managing Director.
  • It is a privilege to lead NEUWAY at this exciting time as we are rapidly generating highly promising data, advancing our EnPC development program and entering into new partnerships," said Dr Ernst.